Decoding the epigenome

Worked with Epinomics
+100 GB
Of Data per Sample
Increased Flexibility and Scalability 2-fold
  • Software Development
  • Tech Advisory


Epinomics approached us with the vision to form a platform ecosystem that leverages deep analytics and processes large data sets to decode the epigenome in order to make sense of personalized medicine data.


Our engineering team was responsible for the design, solution architecture, development, and maintenance of the platform that enables data processing and interaction between Epinomics scientists and their clients as well as partners. It allows users to enter sample data, choose the type of analysis they wanted to run, and keep track of sample processing stages. We also transferred the solution from a monolithic to a microservices architecture which ensured greater flexibility, easier maintenance, and scalability.

Epinomics got acquired by Softbank-backed 10x Genomics

Epinomics develops technologies for epigenetics research. Epigenetics is a buzzing field, as scientists have learned in recent years that sequencing genes is not sufficient to understand human health.

The genome sequencing space is outpacing Moore’s Law

Cost to sequence genetic information has dropped quicker than predicted by Moore’s Law, a long-standing theory that computing power available for the same price doubles about every 18 months to two years. The price of sequencing plummeted from about $10 million to $1,000 in less than a decade, making Moore’s Law look sedate.

Epigenetics refers to external modifications to DNA that turn genes "on" or "off."

To create a practical diagnostic test for a given cancer, several thousand genes must be compared from cancerous and healthy cells, identifying changes in the DNA methylation of one or more genes that correlate with the disease.


Epinomics is revolutionizing personalized medicine through scientific research and deep analytics. Being dedicated to the vision to decode the programming of our genome to drive personalized medicine and proprietary epigenomics technology with 1000x improvement over existing technologies to impact drug development and clinical applications. Since 2018 Epinomics has been acquired by 10x Genomics.


"Furthers 10x Leadership across Genomics Applications Brings Inventors of ATAC-seq Technology to 10x"

Read full article

"10x Genomics is making its first acquisition of a start-up, called Epinomics"

Read full article

Have any questions?
Contact us

See Other Cases

  • Healthcare


Midas Healthcare GmbH, a pharmaceutical leader from Ingelheim, Germany, engaged us along with another marketing agency to develop the website of their new brand ‘LaVieCal’.

  • Other


We developed a brand strategy to Maddox AI that communicates the company’s values, messaging and personality through updated styles and layout.

  • Healthcare

Global Health Corporation

One of the leading Global Pharmaceutical Retailers approached us to develop a global design system.

  • Healthcare

Cannabis Doctors

We worked with Cannabis Doctors to shape their brand strategy and develop their brand identity, logo, guidelines and website.

  • E-Commerce
  • Healthcare


Acting in the highly competitive online pharmacy market, together with Kurando we set up the mobile app for their OTC online shop in less than 12 weeks.

Let's build great digital products together

    Can you help me to explore and validate a product idea?
    How can you help me to scale digital innovation within my organization?
    What skills do you have available?